The Viatris (VTRS) Story — with Bull‑Scenario Price Target Viatris was created in 2020 through the merger of Mylan and Upjohn, Pfizer’s division of older, off‑patent medicines. Overnight, it became one of the largest global players in generic drugs and biosimilars, operating in more than 165 countries.Read more
Viatris aims to restart growth by pushing more new medicines into underserved markets as aging populations need more long-term care, while cutting costs and shifting toward products that can earn better profits. The catch is that much of the business still depends on older, low-priced drugs facing tough regulation and intense competition, which could keep results from improving.Read more
Viatris could get a fresh boost as more countries push cheaper alternatives to branded drugs and as its growing reach in fast‑growing regions brings in new customers. The catch is that drug pricing rules, manufacturing scrutiny, and heavy debt could limit how much of that growth turns into steady profits.Read more
Viatris faces a tough squeeze as drug prices come under pressure and regulators tighten the rules, which could make it harder to keep profits steady in its core low-cost medicines business. The real question is whether newer branded treatments, eye-care products, and overseas growth can offset a heavy debt load and a lineup of aging products.Read more
No trending discussion available.
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
